This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Earnings Preview: Boston Scientific (BSX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Medtronic's LINQ II ICM Gets Multiple Regulatory Approvals
by Zacks Equity Research
Medtronic's (MDT) FDA and CE Mark-approved LINQ II ICM enables physicians to optimize device settings via remote programming, without requiring patients' in-office visits.
Boston Scientific's (BSX) ICM System Receives FDA Approval
by Zacks Equity Research
Boston Scientific's (BSX) new ICM System gets the FDA's nod, thus paving way for better detection and treatment of arrhythmias.
Medical Products Industry's Near-Term Outlook Lacks Spark
by Trina Mukherjee
AI & Robotics can drive the medical products industry amid the coronavirus-induced crisis.
Boston Scientific's Single-Use Duodenoscope Gets TPT Class Nod
by Zacks Equity Research
Boston Scientific's (BSX) EXALT Model D Single-Use Duodenoscope, approved for a TPT payment class by the CMS, will aid Medicare beneficiaries to enjoy the benefits of new and innovative devices.
Boston Scientific (BSX) Launches Monitoring Tool Post FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
How Has BSX Performed 30 Days Post Earnings
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PETQ vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PETQ vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Q1 Earnings Miss, Margins Decline
by Zacks Equity Research
The severity of the COVID-19 outbreak takes a toll on Boston Scientific's (BSX) global sales during the first quarter.
Boston Scientific (BSX) Q1 Earnings Miss Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of -15.15% and 0.76%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Apr 29: BSX, ALGN & More
by Urmimala Biswas
Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products.
3 Medical Product Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Can IC and PI Arms Drive Boston Scientific (BSX) Q1 Earnings?
by Zacks Equity Research
Boston Scientific's (BSX) business trends in the first two months of the quarter in line with its expectations.
Analysts Estimate Boston Scientific (BSX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 MedTech Stocks Likely to Have Braved Coronavirus Blow in Q1
by Sriparna Ghosal
Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.
The Zacks Analyst Blog Highlights: Tesla, Zoetis, Target, Boston Scientific and Moody's
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, Zoetis, Target, Boston Scientific and Moody's
Top Research Reports for Tesla, Zoetis, Target
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), Zoetis (ZTS) and Target (TGT).
New Buyouts Aid Boston Scientific Amid Coronavirus Crisis
by Zacks Equity Research
The current economic turbulence due to the coronavirus outbreak is massively causing depreciation of Boston Scientific's (BSX) stock.
Bull of the Day: Edwards Lifesciences (EW)
by Kevin Cook
While most elective procedures are being deferred, the innovator of minimally-invasive heart valve replacement beats on
3 Medical Stocks Poised to Trounce Market on Coronavirus Scare
by Urmimala Biswas
Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.
Coronavirus to Weigh on These 4 Medical Stocks' Q1 Show
by Sreyoshi Mukherjee
The coronavirus pandemic likely to disrupt the first-quarter performances of players in the MedTech space.
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific and Abbott Laboratories
Coronavirus Ails S&P 500 Index, MedTechs Bear the Brunt
by Urmimala Biswas
S&P 500 MedTech stocks pull the index further down on COVID-19 situation becoming grimmer.
Neovasc (NVCN) Releases Update on Reducer and Tiara Products
by Zacks Equity Research
Neovasc (NVCN) expects an approval from the FDA for Reducer by end of 2020.
Boston Scientific (BSX) Down 12.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.